while in the rapidly evolving area of cancer therapeutics, comprehending the intricate mechanisms of Antibody-Drug Conjugates (ADCs) is important for building efficient solutions. The most promising ways is the use of in vitro bystander outcome assays, which play a pivotal function in boosting therapeutic efficacy. These assays, provided by busines